Under the expanded agreement, Lonza will commission a dedicated manufacturing suite for clinical and commercial production of AdCOVID at its Houston, TX, facility. Securing the limited manufacturing capacity will support the late-stage development and potential future commercialization of the product.

AdCOVID is a candidate that is administered via nasal spray. In preclinical studies, it has been shown to activate systemic immunity and mucosal immunity in the respiratory tract. Altimmune recently began a phase I clinical trial; the company expects data from this study to be released in the second quarter of 2021.

Based on experience with the vaccine platform technology, the company anticipates that AdCOVID could provide immunity of up to one year or more following a single dose. Moreover, the vaccine can be shipped without cold chain logistics and without the need for specialized freezer storage, according to the firm.

Altimmune begins trial of nasal COVID-19 vaccine
Altimmune has begun enrollment in a phase I clinical trial of AdCOVID, a single-dose, intranasal COVID-19 vaccine candidate.

Altimmune submits IND for single dose intranasal COVID-19 vaccine
Altimmune has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration to begin a phase I clinical trial of its...

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...